What Needs to Be in Place Before a First-in-Human Trial Begins Before entering a First-in-Human trial, a drug candidate must be supported by a comprehensive package of scientific, non-clinical and quality evidence
Its typically used in short cycles, either via injection or oral formulations, and is considered one of the most promising peptides for long-term cellular health and lifespan support
GLP-1 alternative
doi: 10.1371/journal.pone.0087466 Summary Keywords oral semaglutide, body composition, fat mass, visceral adipose tissue, fat free mass, skeletal muscle mass, type 2 diabetes, GLP-1RA Citation Volpe S, Lisco G, Fanelli M, Racaniello D, Colaianni V, Lavarra V, Triggiani D, Crudele L, Triggiani V, Sabb C, De Pergola G and Piazzolla G (2023) Oral semaglutide improves body composition and preserves lean mass in patients with type 2 diabetes: a 26-week prospective real-life study